(Q33690495)

28 July 2017

1 reference

title

Biochemical and immunologic mechanisms in atopic dermatitis: new targets for emerging therapies (English)

1 reference

28 July 2017

1 reference

Hanifin JM

1

1 reference

28 July 2017

Chan S

series ordinal

2

1 reference

28 July 2017

language of work or name

English

0 references

publication date

1 July 1999

1 reference

Journal of the American Academy of Dermatology

28 July 2017

published in

1 reference

28 July 2017

volume

41

1 reference

28 July 2017

issue

1

1 reference

28 July 2017

page(s)

72-77

1 reference

Transfer of allergen-specific IgE-mediated hypersensitivity with allogeneic bone marrow transplantation.

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2899%2970410-X

7 January 2021

Biphasic response against aeroallergen in atopic dermatitis showing a switch from an initial TH2 response to a TH1 response in situ: an immunocytochemical study

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2899%2970410-X

7 January 2021

Atopic disease and serum immunoglobulin-E

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2899%2970410-X

7 January 2021

Wheal and erythema allergy in patients with agammaglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2899%2970410-X

7 January 2021

Recombinant interferon gamma therapy for atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2899%2970410-X

7 January 2021

In situ quantification of T-lymphocyte subsets and Langerhans cells in the inflammatory infiltrate of atopic eczema

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2899%2970410-X

7 January 2021

Recombinant interferon-gamma in severe atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2899%2970410-X

7 January 2021

Decreased interferon gamma and increased interleukin-4 production in atopic dermatitis promotes IgE synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2899%2970410-X

7 January 2021

Increased interleukin-4 production by atopic mononuclear leukocytes correlates with increased cyclic adenosine monophosphate-phosphodiesterase activity and is reversible by phosphodiesterase inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2899%2970410-X

7 January 2021

Analysis of the cytokine pattern expressed in situ in inhalant allergen patch test reactions of atopic dermatitis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2899%2970410-X

7 January 2021

IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2899%2970410-X

7 January 2021

Langerhans cells in acute and chronic epidermal lesions of atopic dermatitis, observed by L-dopa histofluorescence, glycol methacrylate thin secretion, and electron microscopy

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2899%2970410-X

7 January 2021

The presence of IgE molecules on epidermal Langerhans cells in patients with atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2899%2970410-X

7 January 2021

Human epidermal Langerhans cells express the high affinity receptor for immunoglobulin E (Fc epsilon RI)

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2899%2970410-X

7 January 2021

Dermal deposition of eosinophil-granule major basic protein in atopic dermatitis. Comparison with onchocerciasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2899%2970410-X

7 January 2021

Assessment of eosinophil and neutrophil participation in atopic dermatitis: comparison with the IgE-mediated late-phase reaction

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2899%2970410-X

7 January 2021

Airway responsiveness in atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2899%2970410-X

7 January 2021

Heterologous desensitization of leukocytes: a possible mechanism of beta adrenergic blockade in atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2899%2970410-X

7 January 2021

Elevated leukocyte cyclic AMP—phosphodiesterase in atopic disease: a possible mechanism for cyclic AMP—agonist hyporesponsiveness

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2899%2970410-X

7 January 2021

Immunochemical characterization of the distinct monocyte cyclic AMP-phosphodiesterase from patients with atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2899%2970410-X

7 January 2021

Phosphodiesterase inhibitors: new opportunities for the treatment of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2899%2970410-X

7 January 2021

Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2899%2970410-X

7 January 2021

The mechanism of action of cyclosporin A and FK506.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2899%2970410-X

7 January 2021

Topical tacrolimus (FK 506): a new milestone in the management of atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2899%2970410-X

7 January 2021

A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2899%2970410-X

7 January 2021

Successful treatment of resistant facial lesions of atopic dermatitis with 0.1% FK506 ointment

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2899%2970410-X

7 January 2021

Tacrolimus (FK506) ointment for atopic dermatitis: a phase I study in adults and children

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2899%2970410-X

7 January 2021

A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2899%2970410-X

7 January 2021

A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2899%2970410-X

7 January 2021

Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2899%2970410-X

7 January 2021

Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2899%2970410-X

7 January 2021

10.1016/S0190-9622(99)70410-X

Identifiers

DOI

1 reference

28 July 2017

1 reference